EMA Withdrawn: Acomplia (rimonabant) — sanofi-aventis

View source ↗

Summary

Acomplia (rimonabant) has been withdrawn from the market by Sanofi-Aventis; status indicates withdrawal for obesity indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Acomplia (rimonabant)

Snippet

Status: Withdrawn. Therapeutic area: Obesity. MAH: sanofi-aventis. Decision date: 17/07/2008